Amphotericin B lipid complex overdosage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
Amphotericin B desoxycholate overdose has been reported to result in cardio-respiratory arrest. Fifteen patients have been reported to have received one or more doses of ABELCET® between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET®. | Amphotericin B desoxycholate overdose has been reported to result in cardio-respiratory arrest. Fifteen patients have been reported to have received one or more doses of ABELCET® between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET®. | ||
If an overdose is suspected | If an overdose is suspected: | ||
#'''Discontinue''' therapy | |||
#'''Monitor''' the patient’s clinical status | |||
#'''Administer''' supportive therapy as required. ABELCET® is '''not hemodialyzable'''.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ABELCET (AMPHOTERICIN B, DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL- AND DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-) INJECTION [SIGMA-TAU PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 06:13, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overdosage
Amphotericin B desoxycholate overdose has been reported to result in cardio-respiratory arrest. Fifteen patients have been reported to have received one or more doses of ABELCET® between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET®.
If an overdose is suspected:
- Discontinue therapy
- Monitor the patient’s clinical status
- Administer supportive therapy as required. ABELCET® is not hemodialyzable.[1]
References
Adapted from the FDA Package Insert.